Zobrazeno 1 - 10
of 15
pro vyhledávání: '"S. Z. Fields"'
Autor:
C. W. Whitney, G. A. Ross, S. Z. Fields, R. A. Beckman, J. H. Malfetano, Daniel L. Clarke-Pearson, S. R. Lane, M. H. DeWitte, Timothy Iveson, P. Hanjani, L. Van Le, Gunnar B. Kristensen
Publikováno v:
Journal of Clinical Oncology. 19:3967-3975
PURPOSE: To evaluate oral topotecan as single-agent, second-line therapy in patients with ovarian cancer previously treated with a platinum-based regimen. PATIENTS AND METHODS: Patients (N = 116) received oral topotecan 2.3 mg/m2 daily for 5 days eve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f65d7602426b3fd3915c4432532b8463
https://doi.org/10.1200/jco.2001.19.19.3967
https://doi.org/10.1200/jco.2001.19.19.3967
Autor:
Kang Shen Yao, James P. Stevenson, Stephen Fox, Richard Scher, S Z Fields, J. B. Krebs, Fran Green, M. Simmonds, R Kosierowski, Peter J. O'Dwyer, C. Broom
Publikováno v:
European Journal of Cancer. 34:1358-1362
The aim of this study was to determine the efficacy and toxicity of topotecan administered as a 21-day continuous intravenous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas. 26 previously untreated patients with advan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49388235d9c19dcebfa61f6f8721ff75
https://doi.org/10.1016/s0959-8049(98)00053-7
https://doi.org/10.1016/s0959-8049(98)00053-7
Autor:
N Levithan, David J. Stewart, S Z Fields, M Kosty, Peter J. O'Dwyer, L N Igwemezie, Ronald M. Bukowski, Glenwood D. Goss, Sanjeev Kaul, David R. Gandara
Publikováno v:
Journal of Clinical Oncology. 13:2835-2841
PURPOSE To assess the pharmacokinetics and bioequivalence of etoposide following intravenous (i.v.) administration of etoposide phosphate (Etopophos; Bristol-Myers Squibb, Princeton, NJ), a prodrug of etoposide, and VePesid (Bristol-Myers Squibb). PA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05ba4edd7110a5543c40bd49a2377a80
https://doi.org/10.1200/jco.1995.13.11.2835
https://doi.org/10.1200/jco.1995.13.11.2835
Publikováno v:
Cancer chemotherapy and pharmacology. 46(3)
Purpose: The purpose of this randomized, two-period crossover study was to determine the pharmacokinetics of orally administered topotecan in the presence and absence of oral ranitidine. Methods: Patients with solid malignant tumors refractory to sta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4e2beeb784ef4ccd553d5d3ba6a4c3c
https://pubmed.ncbi.nlm.nih.gov/11021737
https://pubmed.ncbi.nlm.nih.gov/11021737
Publikováno v:
International Journal of Oncology.
In Phase II oncology studies, response rate has traditionally been used to assess activity. However stabilization of disease (SD) may also provide patient benefit. To assess the value of SD (stabilization of measurable disease for at least 8 weeks) a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10d726ffb00e734b9f87fb57808c413e
https://doi.org/10.3892/ijo.17.3.587
https://doi.org/10.3892/ijo.17.3.587
Publikováno v:
International journal of oncology. 17(3)
In Phase II oncology studies, response rate has traditionally been used to assess activity. However stabilization of disease (SD) may also provide patient benefit. To assess the value of SD (stabilization of measurable disease for at least 8 weeks) a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::484dac38620e50f586e248ccc1870281
https://pubmed.ncbi.nlm.nih.gov/10938402
https://pubmed.ncbi.nlm.nih.gov/10938402
Publikováno v:
International journal of oncology. 15(6)
To assess the value of disease stabilization (SD) as a predictor of survival following chemotherapy, data were analyzed from multicenter clinical trials in small cell lung cancer (SCLC) and ovarian cancer (OC) patients receiving various second-line c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffda0ec8e3cb83b66a35627db43cd5d1
https://pubmed.ncbi.nlm.nih.gov/10568833
https://pubmed.ncbi.nlm.nih.gov/10568833
Autor:
S Z, Fields, D R, Budman, R R, Young, W, Kreis, R, Ingram, P, Schulman, R C, Cherny, J, Wright, J, Behr, C, Snow, L P, Schacter
Publikováno v:
Bone marrow transplantation. 18(5)
Etoposide is a widely used cytotoxic agent with a broad spectrum of activity in human malignancies. This agent has been incorporated into many transplant regimens although toxicity occurs because of its poor water solubility and toxic excipients. Eto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c06f3bb565b1cfeff1cbe7578ee2cbc2
https://pubmed.ncbi.nlm.nih.gov/8932836
https://pubmed.ncbi.nlm.nih.gov/8932836
Autor:
S Z Fields, Kathleen Hock, Willi Kreis, Vincent Vinciguerra, Richard Ingram, Lee P. Schacter, Joann Baer, Daniel R. Budman
Publikováno v:
Cancer chemotherapy and pharmacology. 38(4)
Etoposide phosphate, a water soluble prodrug of etoposide, was evaluated at levels potentially useful in transplantation settings in patients with malignancies. For pharmacokinetic studies of etoposide phosphate in this phase I study, 21 patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8bb77345792bb2a36b8c9e296f7d47d
https://pubmed.ncbi.nlm.nih.gov/8674162
https://pubmed.ncbi.nlm.nih.gov/8674162
Autor:
S Z, Fields, L N, Igwemezie, S, Kaul, L P, Schacter, R J, Schilder, P P, Litam, B S, Himpler, C, McAleer, J, Wright, R H, Barbhaiya
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 1(1)
Etoposide phophate is a phosphate ester prodrug of etoposide designed to improve the pharmaceutical characteristics of the parent compound. A Phase I dose-escalating study of etoposide phosphate was conducted concurrently at two institutions to deter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::52c7a495c9f54f46d209f04f54f442ea
https://pubmed.ncbi.nlm.nih.gov/9815892
https://pubmed.ncbi.nlm.nih.gov/9815892